Ngā hua rapu - Shervin Assassi

Whakamahine hua
  1. 1
    The Role of Type 1 Interferon in Systemic Sclerosis

    The Role of Type 1 Interferon in Systemic Sclerosis mā Minghua Wu, Shervin Assassi

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

    Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? mā Chandra Mohan, Shervin Assassi

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Type I interferon dysregulation in Systemic Sclerosis

    Type I interferon dysregulation in Systemic Sclerosis mā Brian Skaug, Shervin Assassi

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need

    Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need mā Ariane L. Herrick, Shervin Assassi, Christopher P. Denton

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Genetics of scleroderma: implications for personalized medicine?

    Genetics of scleroderma: implications for personalized medicine? mā Shervin Assassi, Timothy R. D. J. Radstake, Maureen D. Mayes, Javier Martı́n

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Role of STAT3 in skin fibrosis and transforming growth factor beta signalling

    Role of STAT3 in skin fibrosis and transforming growth factor beta signalling mā Mesias Pedroza, Sarah To, Shervin Assassi, Minghua Wu, David J. Tweardy, Sandeep K. Agarwal

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit

    Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit mā Vishal Kakkar, Shervin Assassi, Yannick Allanore, Masataka Kuwana, Christopher P. Denton, Dinesh Khanna, Francesco Del Galdo

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis

    Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis mā John D Pauling, Gloria A. Salazar, Hui Lu, Zoë Betteridge, Shervin Assassi, Maureen D. Mayes, Neil McHugh

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Deep Learning Classification of Systemic Sclerosis Skin Using the MobileNetV2 Model

    Deep Learning Classification of Systemic Sclerosis Skin Using the MobileNetV2 Model mā Metin Akay, Yong Du, Cheryl L. Sershen, Minghua Wu, Ting Y. Chen, Shervin Assassi, Chandra Mohan, Yasemin M. Akay

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Does C‐Reactive Protein Predict the Long‐Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis?

    Does C‐Reactive Protein Predict the Long‐Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis? mā Xiaochun Liu, Maureen D. Mayes, Claudia Pedroza, Hilda T. Draeger, Emilio B. González, Brock E. Harper, John D. Reveille, Shervin Assassi

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease

    KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease mā Gloria A. Salazar, Masataka Kuwana, Minghua Wu, Rosa M. Estrada‐Y‐Martin, Binwu Ying, Julio Charles, Maureen D. Mayes, Shervin Assassi

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Osteopontin in Systemic Sclerosis and Its Role in Dermal Fibrosis

    Osteopontin in Systemic Sclerosis and Its Role in Dermal Fibrosis mā Minghua Wu, Daniel J. Schneider, Maureen D. Mayes, Shervin Assassi, Frank C. Arnett, Filemon K. Tan, Michael R. Blackburn, Sandeep K. Agarwal

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Identification of Cadherin 11 as a Mediator of Dermal Fibrosis and Possible Role in Systemic Sclerosis

    Identification of Cadherin 11 as a Mediator of Dermal Fibrosis and Possible Role in Systemic Sclerosis mā Minghua Wu, Mesias Pedroza, Robert Lafyatis, A. J. George, Maureen D. Mayes, Shervin Assassi, Filemon K. Tan, Michael B. Brenner, Sandeep K. Agarwal

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Correlation of interferon‐inducible chemokine plasma levels with disease severity in systemic sclerosis

    Correlation of interferon‐inducible chemokine plasma levels with disease severity in systemic sclerosis mā Xiaochun Liu, Maureen D. Mayes, Filemon K. Tan, Minghua Wu, John D. Reveille, Brock E. Harper, Hilda T. Draeger, Emilio B. González, Shervin Assassi

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Right Bundle Branch Block: A Predictor of Mortality in Early Systemic Sclerosis

    Right Bundle Branch Block: A Predictor of Mortality in Early Systemic Sclerosis mā Hilda T. Draeger, Shervin Assassi, Roozbeh Sharif, Emilio B. González, Brock E. Harper, Frank C. Arnett, Ameena Manzoor, Richard A. Lange, Maureen D. Mayes

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations

    Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations mā Pravitt Gourh, Frank C. Arnett, Shervin Assassi, Filemon K. Tan, Mei Huang, Laura Diekman, Maureen D. Mayes, John D. Reveille, Sandeep K. Agarwal

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease

    A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease mā Dinesh Khanna, Rajeev Saggar, Maureen D. Mayes, Fereidoun Abtin, Philip J. Clements, Paul Maranian, Shervin Assassi, Rajan Saggar, Ram Raj Singh, Daniel E. Furst

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis

    Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis mā Rajpreet K. Arora-Singh, Shervin Assassi, Deborah J. del Junco, Frank C. Arnett, Marilyn Perry, Uzma Irfan, Roozbeh Sharif, Tony Mattar, Maureen D. Mayes

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects

    Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects mā S. Hoa, Marie Hudson, Yves Troyanov, S. Proudman, Jenny Walker, Wendy Stevens, M. Nikpour, Shervin Assassi, Maureen D. Mayes, M. Wang, Murray Baron, M J Fritzler

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis

    Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis mā Tamar F Brionez, Shervin Assassi, John D. Reveille, Thomas J. Learch, Laura Diekman, Michael M. Ward, John C. Davis, Michael H. Weisman, Perry M. Nicassio

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: